Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat

Oncology

Volumn 79, Issue 3-4, 2011, Pages 211-218

  Shitara, Kohei ^a   Ito, Seiji ^a   Sawaki, Akira ^a   Tajika, Masahiro ^a   Kawai, Hiroki ^a   Yokota, Tomoya ^a   Takahari, Daisuke ^a   Ura, Takashi ^a   Muro, Kei ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Chemotherapy; Gastric cancer; Inability to eat; Peritoneal metastasis

Indexed keywords

CISPLATIN; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; METHOTREXATE; TAXANE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEEDING DISORDER; FEMALE; GASTRECTOMY; HUMAN; HYPERALIMENTATION; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUTRITIONAL SUPPORT; OVERALL SURVIVAL; PARENTERAL NUTRITION; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH BYPASS; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; EATING DISORDERS; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79952064777     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320759     Document Type: Article

References (14)

1. International Agency for Research on Cancer: GLOBOCAN 2008 (http://www.dep.iarc.fr/CancerMondial.htm).
2. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S; Japan Clinical Oncology Group Study (JCOG9205): Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mito-mycin in patients with unresectable, ad-vanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003; 21:54-59.
3. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A; Gas-trointestinal Oncology Study Group of the Japan Clinical Oncology Group: Fluoroura-cil versus combination of irinotecan plus cis-platin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009; 10:1063-1069.
4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K Orita H, Takeuchi M: S-1 plus cisplatin ver-sus S-1 alone for first-line treatment of ad-vanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221.
5. Imamura H, IIishi H, Tsuburaya A, Hatake K Imamoto H, Esaki T, Kato M, Furukawa H, Hamada C, Sakata Y: Irinotecan plus S-1 (IRIS) versus S-1 alone as first-line treatment for advanced gastric cancer: preliminary re-sults of a randomized phase III study (GC0301/TOP-002). ASCO, 2007, abstract 4525.
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointes-tinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
7. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI: Capecita-bine/cisplatin versus 5-fluorouracil/cisplat-in as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20: 666-73.
8. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU se-quential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). ASCO, 2009, abstract 4545
9. Kim YH, Yamaguchi K, Bang YJ, Takiuchi H, Kang WK, Sato A, Kang YK, Sakamoto J, Abe C, Sakata Y: Phase II study of biweekly paclitaxel and cisplatin combination chemo-therapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial. Jpn J Clin Oncol 2007; 37: 501-508. (Pubitemid 47335468)
10. Hironaka S, Zenda S, Boku N, Fukutomi A, Yoshino T, Onozawa Y: Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer. Gastric Cancer 2006; 9: 14-18.
11. Imazawa M, Kojima T, Boku N, Onozawa Y Hironaka S, Fukutomi A, Yasui H, Yamazaki K, Taku K: Efficacy of sequential methotrex-ate and 5-fluorouracil (MTX/5FU) in im-proving oral intake in patients with ad-vanced gastric cancer with severe peritoneal dissemination. Gastric Cancer 2009; 12: 153-157.
12. Shitara K, Muro K, Matsuo K: Chemothera-py for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res, in press.
13. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Lipatov O, Al-Sakaff N, See C, Rueschoff J, Van Cutsem E: Pathological features of ad-vanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial (abstract 4556). J Clin Oncol 2009; 27(suppl):15s.
14. Kang YK, Ohtsu A, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Wu J, Langer B, Shah MA: AVAGAST: a randomized, dou-ble-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol 2010;28(suppl):18s; abstract LBA4007.